Register Login
Register to leave comments
  • News bot Oct. 2, 2025, 5:51 p.m.

    📋 Agios Pharmaceuticals, Inc. (AGIO) - Financial Results

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 07:14:03

    Event Type: Financial Results

    Event Details:

    Agios Pharmaceuticals Inc (AGIO) Reports Q3 2022 Financial Results Agios Pharmaceuticals Inc (AGIO) announced its financial results for the period ending Q3 2022. Key Financial Highlights:
    • Revenue: 435
    • Net Income: Not disclosed
    • EPS: Not disclosed
    • Cash and equivalents: 1100154
      • 1 Million in Net U.S. Revenue for First Full Quarter of PYRUKYND® (mitapivat) Sales – – Brian Goff to Become Chief Executive Officer at Agios on August 8, 2022, Leveraging 30+ Years of Biopharma Experience, Including Significant Expertise in Rare Disease and Hematology; Current CEO Jackie Fouse to Become Chair of the Board – – Actively Enrolling Patients in Five PYRUKYND® Pivotal Studies Across Thalassemia, Sickle Cell Disease and Pediatric Pyruvate Kinase (PK) Deficiency – – $
      • 1 Billion of Cash, Cash Equivalents and Marketable Securities as of June 30, 2022 – CAMBRIDGE, Mass., August 4, 2022 – Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism pioneering therapies for genetically defined diseases, today reported

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2022 2021 Change ($) Change (%)
    Cash Equivalents Marketable Securities 1.10M 1.29M $-186.24K -14.48%
    Cost And Expenses Selling General Administrative 29.21K 59.78K $-30.56K -51.13%
    Loss From Operations 91.22K 198.78K $-107.56K -54.11%
    Other Income Net 6.52K 4.31K $2.21K +51.37%
    Net Loss Per Share 1.41 3.41 $-2.00 -58.65%
    Cash and Marketable Securities 1.29M 1.29M $0.00 +0.00%
    Revenue 3.08K 3.91K $-832.00 -21.26%
    Selling, General & Administrative 29.21K 59.78K $-30.56K -51.13%
    Loss from Operations 91.22K 198.78K $-107.56K -54.11%
    Interest Income 92.00 2.49K $-2.40K -96.30%
    Other Income, Net 6.52K 4.31K $2.21K +51.37%
    Net Loss 82.79K 186.58K $-103.79K -55.63%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Agios Pharmaceuticals Inc
    • CIK: 0001439222
    • Ticker Symbol: AGIO
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories